Evaluation of the outcome of oral vinorelbine plus trastuzumab in metastatic breast cancer

Tóm tắt

   Background/Objectives: In the COVID-19 era, switching from an intravenous chemotherapy regimen to an oral regimen reduces the frequency of in-person contact and the duration of infusion. In the HERTANA trial, the vinorelbine plus trastuzumab regimen was considered equivalent to docetaxel plus trastuzumab. We conducted this study to evaluate the outcome of oral vinorelbine plus trastuzumab in metastatic breast cancer.

   Methods: This is a retrospective study of 74 cases of HER2-positive breast cancer, either de novo or recurrent metastatic breast cancer, treated with oral vinorelbine in combination with trastuzumab at HCM City Oncology Hospital from June 14, 2021, to June 14, 2023.

   Aims: The primary endpoint is the overall response rate (ORR). Secondary endpoints include progression-free survival (PFS), median overall survival (mOS), and adverse events (AEs).

   Results: The median progression-free survival was 6.5 months, and the median overall survival was 21.1 months. The response rates at 3 and 6 months were 25.7% and 12.2%, respectively.

   Conclusions: The vinorelbine–trastuzumab regimen is a viable alternative to docetaxel–trastuzumab as a first-line treatment for patients who refuse infusion therapy or are intolerant to docetaxel.

DOI: 10.59715/pntjmp.4.2.4